Vancouver, B.C., January 5, 2018MYM Nutraceuticals Inc. (CSE: MYM) (“MYM”) is excited to announce that Australia will expunge the export ban on cannabis products in February 2018 and allow the worldwide exportation of cannabis-based treatments such as oils, patches, sprays, lozenges and tablets.  The Australian Federal Government has big ambitions for Australia to become the largest producer of medicinal cannabis products in the world.

Australia’s Health Minister Greg Hunt stated, “We would like to be, potentially, the world’s number one medicinal cannabis supplier.  One of the conditions of any license for export is that medicinal cannabis be made available to Australian patients first.  The sector is fully supportive of that. Australian patients come first.  There are now no real government barriers at all to accessing medicinal cannabis.”

This is fantastic news for MYM since it has an Australian joint venture company, Solaris Nutraceuticals, that is currently in the assessment phase of the licensing process to build a 1.2 million square-foot greenhouse facility set to be the largest cannabis production facility in Australia.  MYM expects that exportation of cannabis products from Australia will be big business and could even outstrip domestic sales.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

About Solaris Nutraceuticals Inc.

Solaris Nutraceuticals is an innovative medical technology company headquartered in Sydney, Australia. It has submitted an application and plans with Australia’s Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales, Australia.  Solaris’s corporate mission is to deliver environmentally friendly, sun-grown medicinal-grade cannabis and to develop medicines and treatments for pain management and other medical conditions.  The company’s focus is on innovations that promote, support and deliver improvements in the quality, consistency and cost of medicines to our clients.  For more information, visit www.solarisnutraceuticals.com.

ON BEHALF OF THE BOARD

Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

Investor Relations
Terry Brown
1.855.696.2261
terry@mymarijuana.ca